Oct 10 (Reuters) - Ibio Inc :
* IBIO AND ASTRALBIO PROVIDE UPDATE ON MYOSTATIN PROGRAM FOR OBESITY
* IBIO INC - PLANS NON-CGMP IN VIVO STUDIES WITH EARLY 2025 READOUTS
* IBIO INC - AIMS TO FILE IND APPLICATION FOR MYOSTATIN PROGRAM BY END OF 2025
* IBIO INC - HAS EXCLUSIVE OPTION TO LICENSE THREE CARDIOMETABOLIC TARGETS FROM ASTRALBIO
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.